NGNE - Neurogene Inc Stock Price & Dividend Safety Sector: Healthcare | Exchange: NASDAQ Global Market Current Price & Safety Score Price: 23.54 USD StockBonds Safety Grade: D Altman Z-Score (Bankruptcy Risk): 5.32 StockBond Score: -3.13 Company Description Neurogene Inc is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions Its current pipeline prominently features two key investigational therapies NGN401 an AAV9 gene therapy specifically targeting Rett syndrome and NGN101 which is being developed to address neuronal ceroid lipofuscinosis subtype 5 Batten disease The companys operations are based in New York New York